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Background: In the prospective, randomized TWENTE trial, the zotarolimus-eluting
Resolute stent was at 1 year follow-up non-inferior to the everolimus-eluting Xience V
stent for the primary endpoint target vessel failure. This composite endpoint consisted of
cardiac death, clinically indicated target vessel revascularization, or target vessel-related
myocardial infarction (MI). So far, few long-term data of prospective head-to-head
comparisons between both DES have been reported.
Methods: Patients requiring percutaneous coronary interventions (PCI) with DES
implantation at Thoraxcentrum Twente in Enschede were randomization between Reso-
lute (Medtronic Vascular, Santa Rosa, CA, USA) and Xience V (Abbott Vascular, Santa
Clara, CA, USA) in a 1:1 fashion. Inclusion of all coronary or bypass graft lesions and all
clinical settings was permitted except for primary PCI (i.e. acute ST-elevation myocardial
infarction (STEMI) was an exclusion criterion). Both external monitoring and clinical
event adjudication were performed by an independent external contract research organi-
zation (Cardialysis, Rotterdam, the Netherlands). Two year clinical follow-up was
performed as indicated in the study protocol.
Results: A total of 1,391 patients were enrolled in the TWENTE trial between June 2008
and August 2010. The study population comprised 21.6% diabetics with a vast majority
of complex lesions and “off-label” indications for drug-eluting stents (77.4%). Patients
presented with either stable angina (48.5%) or unstable angina/Non-STEMI (51.5%).
Demographics, baseline angiographic and procedural data, and 2-year clinical follow-up
data will be presented. This includes the primary endpoint of the study: Target vessel
failure (TVF) at 2 year follow-up. Secondary endpoints include the individual components
of the primary endpoint and the incidence of very late stent thrombosis. In addition, results
of subgroup analyses will be reported.
Conclusions: Results of pre-specified analyses of 2-year clinical outcome of the
TWENTE trial will be presented at TCT 2012.
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Background: The ISAR-TEST 5 clinical trial was a large-scale trial powered for clinical
endpoints. It showed non-inferior safety and efficacy of a polymer-free sirolimus and
probucol-eluting stent(SES)compared to a zotarolimus-eluting stent (ZES) at 1 year. We
evaluated 2-year clinical outcomes in the study population and in pre-defined at-risk
subgroups
Methods: In total 3002 patients undergoing PCI with minimal exclusion criteria received
polymer-free SES (n2002) or ZES. Follow-up was performed to 2 years. The primary
endpoint (MACE) was the combined incidence of cardiac death, target vessel-related MI
or target lesion revascularization (TLR) at 2 years. Secondary endpoints comprised:
combined endpoint of death or any MI, TLR and probable or definite stent thrombosis.
MACE was also evaluated in sub-groups according to sex, age, reference vessel diameter
and diabetes.
Results: There was no difference in the occurrence of the primary endpoint between The
polymer-free SES group and the ZES group demonstrated equivalent MACE (15.8%; vs:
15.9%; HR0.98; P0.87), death or MI (9.16% vs. 10.7% ; HR0.83; P0.12), target
lesion revascularization (12.2% vs. 11.9%; HR1.02; P0.89) or stent thrombosis
(0.56% vs.0.40%; HR1.37; P0.59). Sub-group analysis showed no differences in
outcomes between polymer-free SES and ZES in patient sub-groups with the following
characteristics: women, men, those at or above mean study age, patients below mean
study age, vessel reference diameter above study median, vessel reference diameter at or
below the study median, patients with diabetes mellitus or without diabetes mellitus.
subgroup polymer free DES ZES P
AGE67.8 15.9% 17.1% 0.86
AGE67.8 15.6% 14.5% 0.59
FEMALE 16.7% 13.8% 0.21
MALE 15.5% 16.6% 0.32
DIABETES 22.1% 21.3% 0.70
NO DIABETES 13.3% 13.7% 0.82
RD2.79mm 16.7% 18.2% 0.26
RD2.79mm 15.0% 14.5% 0.39
Conclusions: In a large-scale trial powered for clinical endpoints, there were no
differences in safety or efficacy between a polymer-free sirolimus and probucol-eluting
stent and a new generation ZES at 2 years. This was consistenT across all sub-groups.
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Background: Dual antiplatelet therapy (DAPT) with aspirin (ASA) 	 prasugrel (Pras,
10 mg maintenance dose (MD)) in the very elderly was associated with higher rates of
bleeding than with DAPT comprising ASA 	 clopidogrel (Clop 75 mg MD). The
GENERATIONS study was a blinded, randomized cross-over study that assessed the
pharmacodynamics (PD) of 5 mg Pras in the very elderly (75 yrs) vs. 10 mg Pras in
non-elderly (45 to65 yrs) in patients with stable coronary artery disease and included
a comparison with 75 mg Clop. In the present analysis we compared the PD effects of 5
mg Pras with 75 mg Clop in the very elderly cohort.
Methods: In the study, 73 very elderly patients on low-dose ASA, mean age 78.9  3
years, had PD assessments following 12 days of 5 mg Pras or 75 mg Clop. PD assays
included LTA, VN-P2Y12 and VASP and consensus cut-off values of 50% MPA,
235 PRU and 50% PRI defined high on treatment platelet reactivity (HPR).
Results: Absolute measures of mean platelet reactivity (MPA, PRU and PRI) all
indicated greater antiplatelet effects of 5 mg Pras compared to 75 mg Clop (Figure).
Consistent with these data 5 mg Pras also resulted in lower rates of HPR by all 3
consensus cut-off values (Figure).
Conclusions: In very elderly coronary artery disease patients, 5 mg Pras results in greater
suppression of platelet reactivity than 75 mg Clop; accordingly, 5 mg Pras may provide
an alternative approach to DAPT in this high risk population.
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